These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 22099521)

  • 1. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease.
    van Ingen J; Totten SE; Heifets LB; Boeree MJ; Daley CL
    Int J Antimicrob Agents; 2012 Feb; 39(2):173-6. PubMed ID: 22099521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands.
    van Ingen J; van der Laan T; Dekhuijzen R; Boeree M; van Soolingen D
    Int J Antimicrob Agents; 2010 Feb; 35(2):169-73. PubMed ID: 20006470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance.
    van Ingen J; Hoefsloot W; Mouton JW; Boeree MJ; van Soolingen D
    Int J Antimicrob Agents; 2013 Jul; 42(1):80-2. PubMed ID: 23664674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.
    van Ingen J; Egelund EF; Levin A; Totten SE; Boeree MJ; Mouton JW; Aarnoutse RE; Heifets LB; Peloquin CA; Daley CL
    Am J Respir Crit Care Med; 2012 Sep; 186(6):559-65. PubMed ID: 22744719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Extracellular and intracellular activity of sparfloxacin against Mycobacterium avium complex and Mycobacterium xenopi].
    Gevaudan MJ; Bollet C; Mallet MN; de Lamballerie X; Sambuc R; de Micco P
    Pathol Biol (Paris); 1992 May; 40(5):443-9. PubMed ID: 1323093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between the in vitro drug susceptibility of opportunist mycobacteria and their in vivo response to treatment.
    Heginbothom ML
    Int J Tuberc Lung Dis; 2001 Jun; 5(6):539-45. PubMed ID: 11409581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemotherapeutic regimens for nontuberculous mycobacterial infection based on in-vitro susceptibility test results].
    Tsukamura M; Yamori S
    Kekkaku; 1990 May; 65(5):349-57. PubMed ID: 2168003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical isolates of Mycobacterium simiae in San Antonio, Texas. An 11-yr review.
    Valero G; Peters J; Jorgensen JH; Graybill JR
    Am J Respir Crit Care Med; 1995 Nov; 152(5 Pt 1):1555-7. PubMed ID: 7582293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group.
    Shafran SD; Singer J; Zarowny DP; Phillips P; Salit I; Walmsley SL; Fong IW; Gill MJ; Rachlis AR; Lalonde RG; Fanning MM; Tsoukas CM
    N Engl J Med; 1996 Aug; 335(6):377-83. PubMed ID: 8676931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disseminated Mycobacterium simiae infection in patients with AIDS.
    Al-Abdely HM; Revankar SG; Graybill JR
    J Infect; 2000 Sep; 41(2):143-7. PubMed ID: 11023758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Susceptibility Testing of Mycobacterium Simiae: An Emerging Pathogen in Iran.
    Nasiri MJ; Amini S; Nikpor Z; Arefzadeh S; Mousavi SMJ; Goudarzi H
    Infect Disord Drug Targets; 2021; 21(4):619-622. PubMed ID: 32720607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug susceptibility profiling and genetic determinants of drug resistance in Mycobacterium simiae isolates obtained from regional tuberculosis reference laboratories of Iran.
    Daneshfar S; Khosravi AD; Hashemzadeh M
    PLoS One; 2022; 17(8):e0267320. PubMed ID: 35960778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease.
    van Ingen J; Totten SE; Helstrom NK; Heifets LB; Boeree MJ; Daley CL
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6324-7. PubMed ID: 23027189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of nontuberculous mycobacterial infections in pediatric patients.
    Levin RH; Bolinger AM
    Clin Pharm; 1988 Jul; 7(7):545-51. PubMed ID: 2843317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycobacterium simiae Infection in an Immunocompromised Patient without Acquired Immunodeficiency Syndrome.
    Braun-Saro B; Esteban J; Jiménez S; Castrillo JM; Fernández-Guerrero ML
    Clin Infect Dis; 2002 Mar; 34(5):E26-7. PubMed ID: 11810603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nontuberculous mycobacterial skin infections: clinical and bacteriological studies.
    Mahaisavariya P; Chaiprasert A; Khemngern S; Manonukul J; Gengviniij N; Ubol PN; Pinitugsorn S
    J Med Assoc Thai; 2003 Jan; 86(1):52-60. PubMed ID: 12678139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Disease due to Mycobacterium simiae and "Mycobacterium sherrisii" in Argentina].
    Barrera L; Palmero D; Paul R; López B;
    Medicina (B Aires); 2010; 70(4):343-6. PubMed ID: 20679055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of drug susceptibility and DNA fingerprint patterns of clinical isolates of Mycobacterium tuberculosis from Kampala, Uganda.
    Joloba ML; Whalen CC; Cave DM; Eisenach KD; Johnson JL; Okwera A; Morrissey A; Bajaksouzian S; Feagin J; Mugerwa R; Ellner J; Jacobs MR
    East Afr Med J; 2000 Feb; 77(2):111-5. PubMed ID: 10774085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance in Mycobacterium tuberculosis strains isolated from re-treatment cases of pulmonary tuberculosis in Ethiopia: susceptibility to first-line and alternative drugs.
    Abate G; Miörner H; Ahmed O; Hoffner SE
    Int J Tuberc Lung Dis; 1998 Jul; 2(7):580-4. PubMed ID: 9661826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998.
    Laszlo A; Rahman M; Espinal M; Raviglione M;
    Int J Tuberc Lung Dis; 2002 Sep; 6(9):748-56. PubMed ID: 12234129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.